Dados B3 › EGGY3 × JBSS3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | EGGY3 | JBSS3 | year |
|---|---|---|---|
| ROE | 0.0% | 24.8% | 2025 |
| ROIC | 18.7% | 14.4% | 2025 |
| ROA | 9.6% | 5.0% | 2025 |
| Gross margin | 31.8% | 13.1% | 2025 |
| EBIT margin | 19.6% | 4.9% | 2025 |
| Net margin | 9.5% | 2.6% | 2025 |
| Net debt/EBITDA | 1.10x | 2.49x | 2025 |
| Current ratio | 1.23x | 1.60x | 2025 |
| Revenue growth (1y) | 23.2% | 15.3% | 2025 |
| Revenue growth (5y CAGR) | — | 12.2% | no year where both have it |
| Piotroski F-Score | 8/9 | 7/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | EGGY3 | JBSS3 | year |
|---|---|---|---|
| P/E | — | 9.40x | 2025 × 2024 |
| P/B | 2.61x | 2.02x | 2025 × 2024 |
| EV/EBITDA | 4.32x | 4.90x | 2025 × 2024 |
| FCF yield | 27.6% | 17.1% | 2025 × 2024 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:12 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it